Entries |
Document | Title | Date |
20080287467 | Therapeutic Agent for Respiratory Diseases - The invention provides a therapeutic agent for respiratory diseases, which is based on a new activity mechanism of the antagonism to the P2X4 receptor and by which fewer adverse activities of the existing β-stimulants on the cardiovascular system can be expected. The therapeutic agent of the invention is antagonistic to the P2X4 receptor present in bronchial smooth muscle and is used for the treatment of respiratory diseases caused by bronchocontraction such as asthma. | 11-20-2008 |
20090054467 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases - The invention provides compounds of Formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors. | 02-26-2009 |
20090221613 | Use of Adenine-Derived Compounds for the Treatment of Lupus - The invention relates to the use of adenine-derived compounds substituted in the 2- and 9-positions and, optionally, in the N(6)-position of the adenine, for the manufacture of a medicament for use in the treatment of systemic lupus erythematosus (SLE). The compounds can also be used in combination with a second compound used in the treatment of SLE. | 09-03-2009 |
20090298857 | Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 - Treatment of neurodegenerative diseases is achieved using small molecule purine scaffold compounds that inhibit Hsp90 and that possess the ability to cross the blood-brain barrier or are other wise delivered to the brain. | 12-03-2009 |
20100087454 | MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES - A mucosal bioadhesive slow release carrier comprising an active principle, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains at least one bioadhesive natural protein of vegetal origin and preferably a pea protein from the genus | 04-08-2010 |
20100093767 | Mitotic Kinase Inhibitors - The invention relates to inhibitors of enzymes that disrupt the assembly and function of the mitotic spindle, compositions comprising the inhibitors of Formula (I), kits and articles of manufacture comprising the inhibitors and inhibitor compositions, and methods of using the inhibitors and inhibitor compositions. The inhibitors and inhibitor compositions are useful for treating, preventing or modulating diseases in which mitotic kinesins, including kinesin-like spindle protein (KSP), may be involved; symptoms of such diseases; or the effect of other physiological events mediated by mitotic kinesins, including KSP. | 04-15-2010 |
20100120797 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS - This invention relates to novel purinyl derivatives and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels. | 05-13-2010 |
20110136836 | Methods for Altering MRNA Splicing and Treating Familial Dysautonomia and Other Mechanistically Related Disorders - This invention relates to methods for altering the splicing of mRNA in cells. In particular, this invention also relates to methods for increasing the ratio of wild type to misspliced forms of mRNA and corresponding encoded proteins in cells possessing a mutant gene encoding either the i) misspliced mRNA corresponding to the mutant protein or ii) a component in the splicing machinery responsible for processing the misspliced mRNA. In addition, this invention relates to treating individuals having a disorder associated with a misspliced mRNA, such as Familial Dysautonomia or Neurofibromatosis 1, by administering to such an individual a cytokinin such as kinetin. | 06-09-2011 |
20110207753 | METHODS FOR TREATING PAIN - The present invention features methods and compositions for preventing, reducing, or treating a traumatic, metabolic or toxic peripheral nerve lesion or pain including, for example, neuropathic pain, inflammatory and nociceptive pain by administering to a mammal in need thereof a compound that reduces the expression or activity of BH4. According to this invention, this reduction may be achieved by reducing the enzyme activity of any of the BH4 synthetic enzymes, such as GTP cyclohydrolase (GTPCH), sepiapterin reductase (SPR), or dihydropteridine reductase (DHPR); by antagonizing the cofactor function of BH4 on BH4-dependent enzymes; or by blocking BH4 binding to membrane bound receptors. The compounds of the invention may be administered alone or in combination with a second therapeutic agent. | 08-25-2011 |
20110237606 | 3-Deazaneplanocin Derivatives - This invention describes the series of compounds based on the 3-deazaneplanocin A (DZNep) core structure designed to inhibit the function of Polycomb repressive complex 2 (PRC2) proteins. | 09-29-2011 |
20110257204 | Penciclovir or Famciclovir for Treatment of Recurrent Genital Herpes with a One-Day Application - A method for the treatment of recurrent genital herpes, in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of penciclovir or famciclovir, or a pharmaceutically acceptable salt thereof for a treatment period of one day. | 10-20-2011 |
20120028995 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS - The invention relates to compounds of general formula (I) as set forth in the claims as well as to the use of the compounds of the general formula (1) in the medical field, specifically for use in the suppression of DNA synthesis and inflammatory cytokine production as well as in the stimulation of anti-inflammatory cytokine production in vitro and in vivo. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way. | 02-02-2012 |
20120122895 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS - The present invention provides 5,6-bicyclic heteroaryl-containing urea compounds of Formula I or II and use of the same for treating conditions mediated by protein kinase such as VEGFR2, c-Met, PDGFRβ c-Kit, CSF1R, or EphA2. | 05-17-2012 |
20120316185 | Cyclohexyl Amide Derivatives as CRF Receptor Antagonists - There are described cyclohexyl amide derivatives useful as corticotropin releasing factor (CRF) receptor antagonists Formula (I). | 12-13-2012 |
20130310403 | Fluoro-homoneplanocin A and nucleoside derivatives, method for the synthesis thereof, and the pharmaceutical compositions comprising the same as an active component for treatment of cancer - The present invention relates to a fluoro-homoneplanocin A, its nucleoside derivative, and synthetic methods. The novel fluoro-homoneplanocin A and its nucleoside derivative in the present invention have an effect on cancer prevention or treatment, and therefore can be used as anticancer drugs. | 11-21-2013 |